IL2RA and infection: On the other hand, several studies have shown that combining an IL-2R antagonist (e.g., basiliximab) with specific second-line treatments, such as MSCs [46, 51], methotrexate, and vedolizumab [52], can achieve a higher ORR without significantly increasing infections, which could be further explored in patients receiving xenopax treatment.